- TLDR Biotech
- Archive
- Page 14
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | July 23 - 24, 2024
Pfizer's hemophilia A gene therapy posts positive Ph3, Novo Nordisk's Wegovy gets MHRA approval for a new indication, Gilead unveils full dataset for 100% efficacy HIV prevention shot, highway to funding with Autobahn's $100M Series C, FDA expresses doubt about AstraZeneca's lung cancer med prior to adcomm, and Novo Nordisk has their fourth fire of the year
Biotech & Pharma Updates | July 19 - 21, 2024
Eli Lilly ok'd to sell Zepbound in China, a $520M animal health antibody acquisition, Siga lands $113M US smallpox antiviral supply contract, GRO Biosciences GROws with $60.3M Series B, Artiva bests their own expectations with $167M IPO, and ICER isn't happy at all with Pfizer's ATTR heart disease med price
Biotech & Pharma Updates | July 16 - 17, 2024
Roche's obesity pill posts positive Ph1, J&J earnings stay positive despite looming IRA, NGM nabs $122M raise after going private, Sanofi doubles Hyderabad workforce, Actuate's $50M upcoming IPO, FDA launches rare disease innovation hub, and Roche's Genentech bails on Relay Therapeutics partnership
Biotech & Pharma Updates | July 15 - 16, 2024
Cardurion raises $260M for cardiac small molecules, CordenPharma invests nearly a billion in GLP-1 capacity expansion, Sionna gets hands on abandoned AbbVie CF asset, Vertex and Orum partner on new Casgevy conditioning regiment, ICER doesn't like Verona's COPD treatment price
Biotech & Pharma Updates | July 11 - 14, 2024
AbbVie's Rinvoq label expansion application, semaglutide correlates with lowered dementia risks, IDEAYA Biosciences raises over $300M through public offering, two health SPACS launch with a combined $400M, Spark Therapeutics layoffs, and Big Pharma & PBMs play drug price blame game
Biotech & Pharma Updates | July 10 - 11, 2024
Pfizer's one-daily obesity pill moves forward, Illumina competitor lands $277M Series D, Novo Nordisk once-weekly insulin injection rejected by FDA, Novartis to shutter San Diego R&D site, and FTC sues Pharmacy Benefit Managers over insulin prices
